Retension Pharmaceuticals, TRex Bio file for US IPO as biotech momentum continues
Sept 18 (Reuters) — Drug developers Retension Pharmaceuticals and TRex Bio filed their paperwork for U.S. initial public offerings on Friday, reinforcing the biotech pipeline for the fall window. The listings would be the latest in a string of biotech IPOs this year, which analysts say has been supported by a wave of a